Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.

  • HK Yip
  • , AA Youssef
  • , S Chua
  • , WC Hung
  • , Yen-Huey Chen
  • , KH Yeh
  • , CJ Wu
  • , CL Hang

Research output: Contribution to journalJournal Article peer-review

8 Scopus citations

Abstract

Statins are known to reduce high-sensitivity C-reactive protein (hs-CRP) concentrations and improve endothelial function. However, whether statin withdrawal causes re-elevated concentrations of hs-CRP and von Willebrand Factor (vWF) (a marker of endothelial damage) remains unknown. We hypothesized that the concentrations of hs-CRP and vWF are substantially increased in patients with unstable angina pectoris (UAP) and noticeably decreased following coronary stenting along with atorvastatin therapy. However, re-elevations of these biomarker concentrations occurred once again after withdrawing atorvastatin therapy. We serially examined the plasma concentrations of hs-CRP and vWF in 51 patients with UAP before (day 0) and after (days 21, 90, 180, 270) performing coronary artery stenting. The concentrations of these 2 biomarkers were also measured in 30 healthy control subjects. Patients were treated with atorvastatin (40 mg/day orally) for 180 days, after which the therapy was withdrawn. The hs-CRP and vWF concentrations were significantly higher in the patients than in the healthy control subjects before the procedure (both P values < 0.001). The hs-CRP concentration decreased significantly on day 21 (P < 0.001), and further to a substantially lower level on day 180 (P < 0.0001). However, the hs-CRP level significantly increased again on day 270, as compared with that on day 180 (P < 0.001). The vWF plasma concentration decreased gradually to a significantly lower level on day 180. The concentration of this biomarker did not differ between days 180 and 270. In conclusion, although hs-CRP concentrations decreased markedly following combined stenting and atorvastatin therapy, re-elevation after atorvastatin therapy was withdrawn in UAP patients undergoing coronary stenting was not observed. Conversely, restoration of endothelial function was slow and persistent in these patients.
Original languageAmerican English
Pages (from-to)501-509
JournalInternational Heart Journal
Volume47
Issue number4
DOIs
StatePublished - 2006

Keywords

  • Angina, Unstable/blood
  • Angina, Unstable/drug therapy
  • Angina, Unstable/surgery
  • Biological Markers/blood
  • C-Reactive Protein/metabolism
  • Coronary Angiography
  • Coronary Artery Bypass/methods
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Heptanoic Acids/therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
  • Immunoenzyme Techniques
  • Male
  • Middle Aged
  • Nephelometry and Turbidimetry
  • Prognosis
  • Pyrroles/therapeutic use
  • Retrospective Studies
  • Severity of Illness Index
  • Stents
  • Time Factors
  • von Willebrand Factor/metabolism

Fingerprint

Dive into the research topics of 'Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.'. Together they form a unique fingerprint.

Cite this